Proteomic identification of a marker signature for MAPKi resistance in melanoma

MAPK inhibitors (MAPKi) show outstanding clinical response rates in melanoma patients harbouring BRAF mutations, but resistance is common. The ability of melanoma cells to switch from melanocytic to mesenchymal phenotypes appears to be associated with therapeutic resistance. High‐throughput, subcell...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:EMBO J
Glavni autori: Paulitschke, Verena, Eichhoff, Ossia, Gerner, Christopher, Paulitschke, Philipp, Bileck, Andrea, Mohr, Thomas, Cheng, Phil F, Leitner, Alexander, Guenova, Emmanuella, Saulite, Ieva, Freiberger, Sandra N, Irmisch, Anja, Knapp, Bernhard, Zila, Nina, Chatziisaak, Theodora‐Pagona, Stephan, Jürgen, Mangana, Joanna, Kunstfeld, Rainer, Pehamberger, Hubert, Aebersold, Ruedi, Dummer, Reinhard, Levesque, Mitchell P
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2019
Teme:
Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6669927/
https://ncbi.nlm.nih.gov/pubmed/31267558
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/embj.201695874
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items